COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00694980
Recruitment Status : Completed
First Posted : June 11, 2008
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: placebo Drug: rhuMAb Beta7 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta7 Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Ulcerative Colitis
Study Start Date : September 2008
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: placebo
Intravenous and subcutaneous escalating doses

Drug: rhuMAb Beta7
Intravenous and subcutaneous escalating doses

Primary Outcome Measures :
  1. Incidence and nature of laboratory abnormalities [ Time Frame: Through study completion or early study discontinuation ]
  2. Incidence, nature, and severity of adverse events [ Time Frame: Through study completion or early study discontinuation ]

Secondary Outcome Measures :
  1. PK profile and parameters [ Time Frame: Through study completion or early study discontinuation ]
  2. Incidence of antibodies directed against rhuMAb Beta7 [ Time Frame: Through study completion or early study discontinuation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able and willing to provide written informed consent
  • 18-70 years of age
  • Males and females with reproductive potential: Willing to use a reliable method of contraception
  • Diagnosis of ulcerative colitis
  • Eligible to receive biologic therapy
  • Disease duration of >=12 weeks

Exclusion Criteria:

  • Requirement for hospitalization due to severity of ulcerative colitis
  • Moderate to severe anemia
  • Any manifestation of ulcerative colitis or other conditions likely to require, in the investigator's judgment, treatment with >20 mg/day of prednisone, or prednisone equivalent, during the course of the study
  • Pregnant or lactating
  • Lack of peripheral venous access
  • Inability to comply with study protocol
  • History or presence of contraindicated diseases
  • Congenital immune deficiency
  • Active or prior infection with HIV or hepatitis B or C
  • History of severe systemic bacterial, fungal, viral, or parasitic infections
  • History of any other opportunistic infections within 12 weeks prior to initiation of study treatment
  • Received a live attenuated vaccine within 4 weeks prior to screening
  • Hospitalized within 4 weeks prior to screening
  • Received any contraindicated therapy within 12 weeks prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00694980

Layout table for location information
United States, Alabama
Anniston, Alabama, United States, 36207
United States, California
San Francisco, California, United States, 94115
United States, Florida
Gainesville, Florida, United States, 32610
United States, Georgia
Atlanta, Georgia, United States, 30308
United States, Kentucky
Lexington, Kentucky, United States, 40536
United States, Minnesota
Rochester, Minnesota, United States, 55905
United States, New York
Great Neck, New York, United States, 11021
United States, North Carolina
Chapel Hill, North Carolina, United States, 27599
Leuven, Belgium, 3000
Canada, Alberta
Calgary, Alberta, Canada, T2N 2T9
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
Vancouver, British Columbia, Canada, V6Z 2K5
Victoria, British Columbia, Canada, V8V 3P9
Canada, Ontario
London, Ontario, Canada, N6A 4L6
Canada, Quebec
Montreal, Quebec, Canada, H1T 2M4
Berlin, Germany, 13353
Frankfurt, Germany, 60431
Kiel, Germany, 24105
Regensburg, Germany, 93053
Ulm, Germany, 89081
Leiden, Netherlands, 2333 ZA
Maastricht, Netherlands, 6229 HX
Nijmegen, Netherlands, 6525 GA
Utrecht, Netherlands, 3584 CX
United Kingdom
Bristol, United Kingdom, BS2 8HW
London, United Kingdom, SE1 7EH
London, United Kingdom, SW10 9NH
London, United Kingdom, W12 0HS
Newcastle upon Tyne, United Kingdom, NE1 4LP
Nottingham, United Kingdom, NG7 2UH
Sponsors and Collaborators
Genentech, Inc.
Layout table for investigator information
Study Director: Clinical Trials Genentech, Inc.
Layout table for additonal information
Responsible Party: Genentech, Inc. Identifier: NCT00694980    
Other Study ID Numbers: ABS4262g
GA00930 ( Other Identifier: Hoffmann-La Roche )
First Posted: June 11, 2008    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Keywords provided by Genentech, Inc.:
Ulcerative Colitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
rhuMAb Beta7
Gastrointestinal Agents
Immunologic Factors
Physiological Effects of Drugs